anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Periodontitis and atherosclerosis are chronic inflammatory diseases characterized by leukocyte infiltration. We investigated the expression of CCL4, CCR5, c-Jun, c-Fos, NF-κB, and CCL2 as well as the possible mechanism involved in the regulation of CCL2 in human periodontitis tissues and atherosclerotic aorta based on previous research on the CCL4/CCR5/c-Jun and c-Fos/CCL2 pathway leading to CCL2 expression in collagen-induced arthritis (CIA) rat.
METHODS: Sixty-five volunteers were recruited and the condition of their gingiva and coronary arteries were assessed. The subjects were divided into four groups: healthy control, chronic periodontitis (CP), coronary artery diseases (CAD), and noncoronary artery diseases (non-CAD). Total RNA was isolated from gingiva in periodontitis patients and control populations and from the aorta in patients with and without CAD. PCR was used to examine CCL4, CCR5, c-Jun, c-Fos, NF-κB, and CCL2 levels. The production of CCL2 in the gingiva and aorta was analyzed by immunostaining.
RESULTS: PCR revealed that CCL4, CCR5, and CCL2 mRNA levels were increased in CP patients' gingivae and aortas from coronary artery bypass grafting (CABG) patients. Marked c-Jun, c-Fos, and NF-κB gene productions were detected in CP patients' gingivae but did not show statistical differences between the CAD and non-CAD groups. Stronger immunoreactivity against CCL2 was observed in periodontitis gingiva and aorta from CABG patients.
CONCLUSIONS: Our findings suggest that the CCL4/CCR5/c-Jun and c-Fos/CCL2 pathways may be involved in CCL2 expression in periodontitis. CCL4, CCR5, and CCL2 might act as possible nodes to link the presence of periodontitis and atherosclerosis.
A setting selection system for a personal protective equipment device is presented. The system includes an indicia retriever that retrieves a set of indications relevant to the personal protective equipment device. The system also includes a setting analyzer that analyzes a current setting for a device function. The system also includes a setting selector that selects a new setting for the device function based on the retrieved indication. The setting selector automatically adjusts the device function from the current setting to the new setting. The system also includes a setting change recorder that records the change from the current setting to the new setting.
The invention discloses a medicine for treating cancers, and relates to a traditional Chinese medicine. The traditional Chinese medicine is characterized in that the medicine is composed of Hedyotis diffusa, Astragalus mongholicus, Radix Salviae Miltiorrhizae, Trichosanthes kirilowii, Chinese caterpillar fungus, Ganoderma lucidum, Placenta Caprae seu Ovis (Capra hircus and/or Ovis aries), Angelica sinensis, Astragalus mongholicus, Morinda officinalis, Cortex Cinnamomi, Changium smyrnioides, scallion fibrous root, Rhizoma Zingiberis and pepper. The traditional Chinese medicine is prepared by adding water into the raw materials, decocting, separating dregs from the decoction, and keeping the decoction for oral administration; and baking and grinding the dregs into powder for oral administration. The traditional Chinese medicine can be directly made into injection, oral liquid, capsule, powder, ointment, etc. The traditional Chinese medicine has the following significant effects: the traditional Chinese medicine prepared by the method provided by the invention mainly comprises food materials, has the effects of tonifying Qi and nourishing blood, harmonizing stomach and tonifying spleen, warming spleen and stomach for dispelling cold, restoring Yang and invigorating pulses, diminishing swelling and removing stasis, supporting healthy energy and improving immunologic function, and is suitable for patients with various cancers. The medicine has the following significant effects: the traditional Chinese medicine prepared by the method is mainly used for treatment and achieves the advantages of clearing away heat and dispersing stasis, promoting urination and expelling toxin, promoting blood circulation and removing stasis, tonifying Qi and nourishing blood, warming spleen and stomach for dispelling cold, diminishing swelling and removing stasis, and supporting the healthy energy and improving immunologic function, thereby being suitable for various cancer patients.
<P>PROBLEM TO BE SOLVED: To provide a method for efficiently obtaining a liposome without using an organic solvent, to provide a stable chitosan-modified liposome using the method and to provide applications of the liposome obtained by the method for production.  <P>SOLUTION: A suspension in which the liposome is dispersed in an aqueous phase is obtained as follows. A phospholipid and/or a glycolipid are used as a membrane lipid and one or more kinds of hydrophilic medicinally effective ingredients and/or lipophilic medicinally effective ingredients are used as an included substance. Water, the included substance and a low- or a high-molecular modifying substance for modifying the liposome and/or an aqueous solution prepared by dissolving or dispersing one or more kinds of dissolving adjuvants therein and gaseous carbon dioxide are sealed in a pressure vessel and stirred while being held at 0-100°C temperature under 30-500 atm pressure for 0.5-5 h. Thereby, an emulsion of CO<SB>2</SB>/H<SB>2</SB>O in which the emulsion of the gaseous carbon dioxide is dispersed in water is obtained. The gaseous carbon dioxide is taken out of the pressure vessel to afford a suspension in which the liposome is dispersed in the aqueous phase remaining in the pressure vessel or in the aqueous phase discharged while being accompanied with the carbon dioxide. The method for producing the liposome and the applications of the liposome obtained by the method for production are provided.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The waiting list group waits 6 months after assessment and allocation and is reassessed after 6 and 12 months. Both groups are reassessed after 24 months, and the second part of the study is a one group longitudinal cohort study.
A computer implemented method and system for improving drug treatment of patients in local communities by providing drug treatment protocols for particular disease states, such as Diagnosis Related Group (DRG) classifications. The protocol contains ranked recommendations for drug treatments of the disease state, and the computer system collects information about the risks and benefits of the drug treatments. The information collected about the treatments is used to modify the rankings of the drug treatments in the protocol. In one specific embodiment of the system, where the disease state has a microbial etiology and the treatments are antimicrobial drugs, the emergence of drug resistance is quickly detected by determining the percentage of microbial isolates that are found to be resistant to antimicrobial therapy in the community where the therapy is being provided (such as a community hospital or city-wide health care system). An increase in the percentage of resistant isolates produces a re-ranking of recommended drug therapies to avoid further use of the drug to which resistance has developed, and helps quickly introduce more effective drugs that will improve the effectiveness and lower the cost of treatment. In yet other embodiments, a sum of medication (e.g. dosing) errors and adverse effects (e.g. allergic reactions) are tracked by the system to identify drugs that are poorly tolerated in particular populations served by the hospital where the treatment is being provided. Data is collected about the safety and effectiveness of all types of drug therapies in the community being served, and this data is used to modify the drug protocols.
A B S T R A C T            A preparation for rehydrating monogastric animals including human beings and new-born ruminants suffer-ing from diarrhoea which preparation is intended for being mixed in water comprises an absorbent intumes-cent agent, electrolytes and lactose-decomposing enzymes(s) and possible roughage, taste corrigents and dyestuffs. The intumescent agent constitutes 20-70% according to weight, preferably 40-43%, the electrolytes constitute 40-60% according to weight, preferably 53-57%, and the enzyme or enzymes consti-tute 0.01-5% according to weight, preferably 0.025-0.027% and the balance is made up of roughage, taste corrigents and/or dyestuffs, where one type of dye-stuff is wheat bran.            It has proved particularly advantageous that the intumescent agent is vegetable fibres from the family plantaginacea and the enzyme is lactase with pH-optimum between 2 and 10, and the electrolytes are a mixture of two or more of the substances magnesium oxide, citric acid, potassium chloride, sodium citrate, sodium chloride, sodium bicarbonate and glucose. An optimum effect is achieved when the fibres are dried crushed seed coats of plantago ovata.            An agent for rehydrating animals suffering from diarr-hoea which maybe cured in very few days is thereby ob-tained thus avoiding deaths and loss of weight. The vast majority of cases on non-infectious diarrhoea among one-stomached animals can be cured in very few days.
Long term follow-up of the patients with delayed TSH elevation or subclinical hypothyroidism has been seldom reported. The purpose of this study was to explore the diagnostic criteria for subclinical hypothyroidism and the initial dosage of L-thyroxine through long-term follow up for infants with hyperthyrotropinemia，and evaluate the curative effect.All live-born neonates in province took part in the screening program from October, 1999 to September ,2006. Laboratory tests are performed as a time resolved fluoro-immunoassay (TRFIA). TSH is measured with a cut-off \> 9 mU/L. The diagnostic standard for subclinical hypothyroidism was: TSH ≥ 20 mU/L, T3 and T4 normal or low-normal ,or TSH \> 5.6 mU/L and \< 20 mU/L on initial determination and on follow-up or TSH levels increase on follow-up and/or gradually declining T4 levels.L-Thyroxine was administered for substitution therapy. After 2 years therapy，allround evaluation was performed. Compare the correlation to effects with different level of TSH、starting time of therapy and environment. Compare the effects between subclinical、temporary and permanent hypothyroidism.
PURPOSE: Bariatric surgery has been reported to produce durable weight loss in the management of obesity; sleeve gastrectomy (SG) is the most common bariatric procedure. Obesity is a common comorbidity of inflammatory bowel disease (IBD), and the impact of IBD on short-term SG outcomes has not been widely reported. This study assessed whether IBD was associated with adverse post-SG outcomes.
MATERIALS AND METHODS: Hospitalizations of patients undergoing SG in the United States were identified using the 2010-2020 Nationwide Readmissions Database (NRD) and stratified by IBD diagnosis. The SG cohort was propensity-matched based on age, biological sex, body mass index (BMI), comorbid diabetes, hypertension, depression, chronic obstructive pulmonary disease, and discharge in quarter four. Primary aims were to compare in-hospital mortality, post-operative complications, and all-cause 90-day readmission between patients with and without IBD. Secondary outcomes were length of stay (LOS) and total hospital cost.
RESULTS: A total of 2030 hospitalizations were matched. The odds of complication were 48% higher for hospitalizations of patients with IBD (11.1% vs. 7.8%; aOR 1.48, aOR 95% CI 1.10-2.00, p = .009). The most common complication was nausea (4.9% vs. 3.7%, p = .187). No statistically significant difference was observed for all-cause 90-day readmissions, LOS, or hospital cost.
CONCLUSION: Hospitalizations of patients with IBD who underwent SG experienced significantly higher post-operative complication rates. However, the similar lengths of stay and readmission rates compared to propensity-matched SG hospitalizations without IBD suggest many complications were minor. SG remains a safe weight loss procedure for patients suffering from IBD and obesity.
Bone marrow collection and peripheral blood collection from ten patients with untreated AL amyloidosis will be evaluated to determine feasibility of isolating a plasma cell clone. An additional three teaspoons of bone marrow and 4 teaspoons of blood will be collected at the time of standard blood draw and bone marrow biopsy before receiving any treatment. There will be no extra procedures or visits specifically for this research.
The criteria for inclusion as a patient with vestibular neuritis involving the superior division (superior VN) included the following: (1) acute onset of vertigo, (2) the appearance of mixed horizontal and torsional nystagmus, (3) impaired horizontal semicircular canal (SCC) function on head-impulse test and a unilaterally absent or reduced caloric response (i.e., a caloric paresis score \> 25%), (4) intact inferior division of vestibular nerve as evidenced by normal cVEMP and normal head-impulse test for vertical SCCs, and (5) the absence of auditory and neurologic signs. Thirty patients (aged 32-82 years; mean age, 51.7 years; 16 males) fulfilled the criteria of superior VN.
Participants randomized to the experimental arm will receive a minimal cue after completing the baseline survey. A follow up survey will be sent 9 months after completion of the minimal cue to assess whether the participant received CRCS. If the participant has not had CRCS they will receive a more intensive telephone linked communication intervention. A second follow up will be sent 9 months after the TLC is delivered to assess final screening status.
The recommended starting dose of AllerNaze for most patients is 200 mcg per day given as 2 sprays (approximately 50 mcg/spray) in each nostril once a day. The maximum dose should not exceed 400 mcg per day. If the 400 mcg dose is used, it may be given either as a once a day dosage (4 sprays in each nostril) or divided into two daily doses of two sprays/nostril twice a day.

The nasal spray pump must be primed before AllerNaze is used for the first time. To prime the pump, press down on the shoulder of the white nasal applicator using your forefinger and middle finger while supporting the base of the bottle with your thumb. Press down and release the pump until it sprays 3 times or until a fine mist is observed (see DIRECTIONS FOR USE).

Some patients may obtain relief of symptoms sooner when started on a 400 mcg per day dose of AllerNaze than with 200 mcg per day. Onset of significant relief of nasal symptoms was seen within two days after starting treatment at 400 mcg once daily. A starting dose of 400 mcg per day may be considered in patients when starting therapy with AllerNaze in cases where a faster onset of relief is desirable. Generally, maximum relief of symptoms may take several days or up to one week to occur.

After symptoms have been brought under control, patients should be titrated to the minimum effective dose to reduce the possibility of adverse effects.

If relief of symptoms is not achieved after 14-21 days of AllerNaze therapy given in an adequate dose, AllerNaze should be discontinued and alternative diagnosis and therapies considered.

AllerNaze is not recommended for use in persons under 12 years of age since its safety and effectiveness have not been established in this age group.
The adaptive immune system allows a higher immune response to be obtained, as well as the establishment of the immunological memory, where each pathogen is remembered by an antigen characteristic of this pathogen in particular. The adaptive immune system allows a higher immune response to be obtained, as well as the establishment of the immunological memory, where each pathogen is remembered by an antigen characteristic of this pathogen in particular. This response generates immunological memory producing, in most cases, permanent immunity against the disease. The cells of the adaptive immune system are a special class of leukocytes, known as lymphocytes. The B and T cells are the main class of lymphocytes and result from pluripotent hematopoietic stem cells. The B and T cells contain receptor molecules that recognize specific targets. The T cells recognize a strange target, as a pathogen, manly after the antigens (small fragments of pathogens) have been processed and presented in com bination with an own receptor. Included is a normal saline solution of 80% to 90% exclusively for being used in tissue culturing, which is sterilized by the membrane and free of pyrogens. All these components are mixed in an amber glass container of 100ml, with 50 ml of solution under a range of 40 ml to 60 ml.
Doxorubicin (DOX) is an anti-tumor agent for chemotherapy, but its use is often hindered by the severe and life-threatening side effect of cardiovascular toxicity. In recent years, studies have focused on dysregulated iron metabolism and ferroptosis, a unique type of cell death induced by iron overload, as key players driving the development of DOX-induced cardiotoxicity (DIC). Recent advances have demonstrated that DOX disturbs normal cellular iron metabolism, resulting in excessive iron accumulation and ferroptosis in cardiomyocytes. This review will explore how dysregulated iron homeostasis and ferroptosis drive the progression of DIC. We will also discuss the current approaches to target iron metabolism and ferroptosis to mitigate DIC. Besides, we will discuss the limitations and challenges for clinical translation for these therapeutic regimens.
Extramedullary plasmacytoma of the larynx is an extremely rare entity accounting for 0.04-0.45% of malignant tumours of the larynx. The objective of this clinical case report is to highlight the diagnosis and management of a unique case such as this. A 77-year-old gentleman presented with complaints of hoarseness for 1 year. Computed tomography image revealed a soft tissue mass lesion involving the right true vocal cord. Direct laryngoscopic biopsy was performed and subjected to histopathological examination, which showed collection of plasma cells. Immunohistochemistry confirmed the presence of Kappa and Lambda cells. Multiple myeloma (MM) was ruled out. The patient received radical intent radiation therapy using 3DCRT technique with a dose of 50Gy in 25# over 5 weeks. He experienced improvement in hoarseness on subsequent follow-up visits. At 1-year follow up, positron emission tomography computed tomography showed near total resolution of disease with no progression to MM. Radiation therapy alone is known to achieve good local control, recurrence free survival, and organ preservation in such cases.
1,225,076. Composition comprising 3-6-diaminothioxanthene-10,10-dioxides. UPJOHN CO. 31 Oct., 1969 [1 Nov., 1968], No. 53550/ 69. Heading A5B. A pharmaceutical composition comprises 3,6- diaminothioxanthene-10,10-dioxide of the formula: or an acid addition salt thereof and a carrier or diluent. The compositions may be in forms suitable for oral or parenteral use or in the form of suppositories; or a food premix for treating domestic birds and animals. The compositions may also contain other anticonvulsant agents such as mephentoin, ethotoin, primidone, phensuximide, paramethadione, diphenylhydantoin or trimethadione, barbiturates such as phenobarbital, mephobarbital and metharbital, muscle relaxants such as meprobamate and chlorphenesin carbamate, antianxiety agents such as chlordiazepoxide, diazepam and oxazepam and stimulants such as desoxyephedrine and amphetamine. Ascorbic acid and chlorobutanol may also be present.
The present invention relates to a formulation of a capsule medicine for treating gastropathy and a preparation technology thereof, which is used for treating epigastric discomfort, pain, abdominal distention, poor appetite, sour regurgitation, heartburn, etc. The formulation of the capsule for treating gastropathy comprises that liquorice, houbu, atractylodes rhizome and egg husk are adopted as raw materials, and the proportioning is 30% of liquorice, 30% of houbu, 15% of atractylodes rhizome and 25% of egg husk. The proportion can be adjusted in a range of 3%. Single medicine is respectively processed. When the liquorice is processed, a glycyrrhizic acid ingredient is removed, and a gastropathy ingredient which does not contain glycyrrhizic acid is used to obviously reduce the side effect. The egg husk is pulverized by ultrasonic and processed by radioactivity. Thus, the preparation is stable, reliable, easily stored and well absorbed. Effective ingredients of houbu and atractylodes rhizome are extracted. Effective ingredients of the four medicines are mixed according to proportion to prepare a capsule preparation which is favourable for storage and administration.
PURPOSE: Prebiotics are defined as substances which selectively promote beneficial gut microbes leading to a health benefit for the host. Limited trials have been carried out investigating their effect on the microbiota composition of individuals afflicted by functional constipation with equivocal outcomes. In a 21-day randomised, controlled clinical trial involving 61 adults with functional constipation, a prebiotic formulation with partially hydrolysed guar gum and acacia gum as its main ingredients, significantly increased complete spontaneous bowel motions in the treatment group. This follow-up exploratory analysis investigated whether the prebiotic was associated with changes to the composition, richness, and diversity of the faecal microbiota.
METHODS: Participants provided a faecal specimen at baseline and on day 21 of the intervention period. Whole genome metagenomic shotgun sequencing comprehensively assessed taxonomic and functional composition of the microbiota.
RESULTS: Linear mixed effects regression models adjusted for potential confounders showed a significant reduction in species richness of 28.15 species (95% CI - 49.86, - 6.43) and Shannon diversity of 0.29 units (95% CI - 0.56, - 0.02) over the trial period in the prebiotic group. These changes were not observed in the control group, and functional composition was unchanged in both groups.
CONCLUSION: In adults with functional constipation, the intake of a prebiotic formulation was associated with a decline of species richness and Shannon diversity. Further research regarding the associations between prebiotics and the composition and function of the gut microbiota is warranted.
PURPOSE:To obtain a carcinostatic agent having excellent carcinostatic action and extremely useful as a drug or for therapeutic treatment, by using a specific polypeptide produced by a microorganism of genus Bacillus as an active component. CONSTITUTION:A polypeptide having a mol.wt. of 25,000, produced by a microorganism of genus Bacillus and existing in the cultured liquid of said microorganism as an insoluble component is extracted with an alkaline aqueous solution. The obtained polypeptide soluble in the alkaline aqueous solution is used as an active component of the objective carcinostatic agent. It is already known that Bacillus thuringiensis which is a microorganism of genus Bacillus produces a crystalline toxin consisting of a polypeptide in the microbial cell in sporulation and the toxin exhibits insecticidal action against specific insects. However, it is absolutely novel finding that the aforementioned specific polypeptide has a carcinostatic activity.
PURPOSE: A method for manufacturing zirconia teeth is provided to make the color of a dental implant similar to the color of a natural tooth. CONSTITUTION: A method for manufacturing zirconia teeth is constituted as follows. Typodont is scanned(S10). According to the generated data, zirconia is processed and a dental implant is molded(S20). The dental implant is dried for 18-22 minutes and cooled at the room temperature(S30). Different kinds of liquid are manufactured(S40). The root, body, and root of the dental implant are coated with different kinds of liquid through coloring steps and are dried(S50). The colored dental implant is fired at 1500-1550deg.C(S60).